Related Experiment Videos
Single dose therapy with temocillin in acute gonorrhoea
Drugs
|January 1, 1985
Summary
Temocillin demonstrates strong effectiveness against gonorrhea, including penicillin-resistant strains. Clinical trials showed high cure rates with a single intramuscular dose, indicating favorable safety and tolerance.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Neisseria gonorrhoeae infections pose a significant public health challenge.
- Penicillinase-producing strains complicate treatment options.
- Novel therapeutic agents are needed to combat gonorrhea.
Purpose of the Study:
- To evaluate the in vitro activity of temocillin against gonococci.
- To assess the clinical efficacy and safety of temocillin in treating gonorrhea.
Main Methods:
- In vitro susceptibility testing of temocillin against penicillin-sensitive and penicillinase-producing Neisseria gonorrhoeae.
- Clinical trials involving intramuscular administration of temocillin (0.5 g or 1.0 g).
- Monitoring of treatment outcomes and adverse events in patients.
Main Results:
- Temocillin exhibited pronounced in vitro activity against both susceptible and resistant gonococci.
- A single intramuscular injection achieved high eradication rates: 91% in 75 patients and 94% in 192 patients.
- The drug was well-tolerated systemically and locally, with no serious side effects reported.
Conclusions:
- Temocillin is a highly effective antibiotic for treating gonorrhea.
- Its favorable safety profile and efficacy against resistant strains make it a valuable therapeutic option.